### Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 5

### REGENERON PHARMACEUTICALS INC

securities beneficially owned directly or indirectly.

Form 5

February 06, 2007

FORM								OMB A	PPROVAL	
Check thi		RITIES AND EXCHANGE COMMISSION ashington, D.C. 20549					3235-0362 January 31, 2005			
to Sectior Form 4 or 5 obligati may conti	r Form ANN ons		ATEMENT OF CHANGES IN BENI DWNERSHIP OF SECURITIES				EFICIAL	Estimated a burden hou response	average Irs per	
See Instru 1(b). Form 3 H Reported Form 4 Transactic Reported	Filed purs Soldings Section 17(a	) of the Publi	on 16(a) of the ic Utility Holdine Investment C	ng Comp	any A	ct of	1935 or Sectio	n		
	Address of Reporting I CR LEONARD S	Sym	suer Name <b>and</b> Ti lbol GENERON	cker or Trac	ding		5. Relationship of Issuer			
			IARMACEUTICALS INC				(Check all applicable) _X_ Director _X_ 10% Owner			
(Last)	(First) (N	(Mo	3. Statement for Issuer's Fiscal Year Ended —				_X_ Officer (give title Other (specify below) Chief Exec Officer & President			
777 OLD S ROAD	AW MILL RIVE		27/2000							
	(Street)	4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Reporting  (check applicable line)			
TARRYTO	WN, NY 1059	21					_X_ Form Filed by Form Filed by ! Person	One Reporting P More than One R		
(City)	(State)	(Zip)	Table I - Non-De	rivative Se	curitie	s Acqu	ired, Disposed of	f, or Beneficial	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			Beneficially Owned at end	Form: Direct (D) or Indirect (I)	Indirect Beneficial Ownership	
				Amount	(A) or (D)	Price	of Issuer's Fiscal Year (Instr. 3 and 4)	(Instr. 4)	(Instr. 4)	
Common Stock	12/29/2006	Â	G	500	D	\$0	61,165	D	Â	
Common Stock	Â	Â	Â	Â	Â	Â	900	I	by Son	
Reminder: Rep	port on a separate line	for each class of	f Persons w	nho respoi	nd to 1	the co	llection of info	rmation	SEC 2	

contained in this form are not required to respond unless

the form displays a currently valid OMB control number.

(9-02)

#### Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 5

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

De

(In

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	Number I of (Derivative Securities Acquired (A) or Disposed of (D)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
Class A	•	2	2	•		5) (D)	Date Exercisable	Expiration Date	Title  Common	Amount or Number of Shares
Stock	Â	Â	Â	Â	Â	A	(1)	(1)	Stock	1,710,790
Class A Stock	Â	Â	Â	Â	Â	Â	(1)	(1)	Common Stock	29,275

## **Reporting Owners**

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
SCHLEIFER LEONARD S 777 OLD SAW MILL RIVER ROAD TARRYTOWN, NY 10591	ÂX	ÂX	Chief Exec Officer & President	Â		

## **Signatures**

Person

/s/\*\*Leonard S.
Schleifer

\*\*Signature of Reporting

Date

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is not applicable in this case.

Note: File three copies of this Form, one of which must be manually signed. If space provided is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2